Innoviva (INVA) Research & Development (2010 - 2026)
Innoviva (INVA) posted Research & Development of $5.2 million for Q1 2026, down 79.88% on a QoQ basis from $26.0 million in Q3 2025, and up 19.22% year-over-year from $4.4 million in Q1 2025.
Innoviva (INVA) Research & Development (2010 - 2026) Analysis & Trends
Innoviva's Research & Development history runs 15 years deep, the most recent figure standing at $5.2 million for Q1 2026.
- Quarterly Research & Development rose 19.22% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.7 million (up 109.72% YoY) and the FY2025 annual result came in at $30.6 million, up 124.14% from the prior year.
- Research & Development was $5.2 million for Q1 2026 at Innoviva, down from $26.0 million in the prior quarter.
- Across five years, Research & Development topped out at $31.6 million in Q3 2023 and bottomed at $2.6 million in Q2 2024.
- A 5-year average of $13.1 million and a median of $10.0 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 36436.84% — and 2024, when it tumbled 82.92%.
- Innoviva's Research & Development stood at $31.4 million in 2022, then rose by 0.38% to $31.6 million in 2023, then slumped by 68.36% to $10.0 million in 2024, then surged by 160.78% to $26.0 million in 2025, then tumbled by 79.88% to $5.2 million in 2026.
- Business Quant data shows INVA's Research & Development at $5.2 million in Q1 2026, $26.0 million in Q3 2025, and $8.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | 5.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.24 Mn |
| Sep 30, 2025 | 26.05 Mn |
| Jun 30, 2025 | 7.98 Mn |
| Mar 31, 2025 | 4.40 Mn |
| Sep 30, 2024 | 9.99 Mn |
| Jun 30, 2024 | 2.56 Mn |
| Mar 31, 2024 | 3.88 Mn |
| Sep 30, 2023 | 31.57 Mn |
| Jun 30, 2023 | 14.99 Mn |
| Mar 31, 2023 | 12.59 Mn |
| Sep 30, 2022 | 31.45 Mn |
| Jun 30, 2022 | 13.88 Mn |
| Mar 31, 2022 | 5.84 Mn |
| Sep 30, 2021 | 536,000.00 |
| Jun 30, 2021 | 38,000.00 |
| Mar 31, 2021 | 49,000.00 |
| Dec 31, 2020 | 219,000.00 |
| Sep 30, 2020 | 1.01 Mn |
| Jun 30, 2020 | 559,000.00 |
| Dec 31, 2017 | 342,000.00 |